INTRODUCTION: Recent discoveries of inherited glioma risk loci and acquired IDH mutations are providing new insights into glioma etiology. IDH mutations are common in lower grade gliomas and secondary glioblastomas and uncommon in primary glioblastomas. Because the inherited variant in 11q23 has been associated with risk of lower grade glioma and not with glioblastomas, we hypothesized that this variant increases susceptibility to IDH-mutated gliomas, but not to IDH-wild-type gliomas. METHODS: We tested this hypothesis in patients with glioma and controls from the San Francisco Adult Glioma Study, the Mayo Clinic, and Illumina controls (1102 total patients, 5299 total controls). Case-control additive associations of 11q23 risk alleles (rs498872, T allele) were calculated using logistic regression, stratified by tumor IDH status (mutated or wild-type) and by histology and grade. We also adjusted for the recently discovered 8q24 glioma risk locus rs55705857 G allele. RESULTS: The 11q23 glioma risk locus was associated with increased risk of IDH-mutated gliomas of all histologies and grades (odds ratio [OR] = 1.50; 95% confidence interval [CI] = 1.29-1.74; P = 1.3X10(-7)) but not with IDH-wild-type gliomas of any histology or grade (OR = 0.91; 95% CI = 0.81-1.03; P = 0.14). The associations were independent of the rs55705857 G allele. CONCLUSION: A variant at the 11q23 locus increases risk for IDH-mutated but not IDH-wild-type gliomas, regardless of grade or histology.
INTRODUCTION: Recent discoveries of inherited glioma risk loci and acquired IDH mutations are providing new insights into glioma etiology. IDH mutations are common in lower grade gliomas and secondary glioblastomas and uncommon in primary glioblastomas. Because the inherited variant in 11q23 has been associated with risk of lower grade glioma and not with glioblastomas, we hypothesized that this variant increases susceptibility to IDH-mutated gliomas, but not to IDH-wild-type gliomas. METHODS: We tested this hypothesis in patients with glioma and controls from the San Francisco Adult Glioma Study, the Mayo Clinic, and Illumina controls (1102 total patients, 5299 total controls). Case-control additive associations of 11q23 risk alleles (rs498872, T allele) were calculated using logistic regression, stratified by tumor IDH status (mutated or wild-type) and by histology and grade. We also adjusted for the recently discovered 8q24 glioma risk locus rs55705857 G allele. RESULTS: The 11q23 glioma risk locus was associated with increased risk of IDH-mutated gliomas of all histologies and grades (odds ratio [OR] = 1.50; 95% confidence interval [CI] = 1.29-1.74; P = 1.3X10(-7)) but not with IDH-wild-type gliomas of any histology or grade (OR = 0.91; 95% CI = 0.81-1.03; P = 0.14). The associations were independent of the rs55705857 G allele. CONCLUSION: A variant at the 11q23 locus increases risk for IDH-mutated but not IDH-wild-type gliomas, regardless of grade or histology.
Authors: Kathleen M Egan; Reid C Thompson; L B Nabors; Jeffrey J Olson; Daniel J Brat; Renato V Larocca; Steven Brem; Paul L Moots; Melissa H Madden; James E Browning; Y Ann Chen Journal: J Neurooncol Date: 2011-01-04 Impact factor: 4.130
Authors: Robert B Jenkins; Margaret R Wrensch; Derek Johnson; Brooke L Fridley; Paul A Decker; Yuanyuan Xiao; Thomas M Kollmeyer; Amanda L Rynearson; Stephanie Fink; Terri Rice; Lucie S McCoy; Chandralekha Halder; Matthew L Kosel; Caterina Giannini; Tarik Tihan; Brian P O'Neill; Daniel H Lachance; Ping Yang; Joseph Wiemels; John K Wiencke Journal: Cancer Genet Date: 2011-01
Authors: Matthias Simon; Fay J Hosking; Yannick Marie; Konstantinos Gousias; Blandine Boisselier; Catherine Carpentier; Johannes Schramm; Karima Mokhtari; Khe Hoang-Xuan; Ahmed Idbaih; Jean-Yves Delattre; Mark Lathrop; Lindsay B Robertson; Richard S Houlston; Marc Sanson Journal: Clin Cancer Res Date: 2010-09-16 Impact factor: 12.531
Authors: D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler Journal: Science Date: 2008-09-04 Impact factor: 47.728
Authors: C Houillier; X Wang; G Kaloshi; K Mokhtari; R Guillevin; J Laffaire; S Paris; B Boisselier; A Idbaih; F Laigle-Donadey; K Hoang-Xuan; M Sanson; J-Y Delattre Journal: Neurology Date: 2010-10-26 Impact factor: 11.800
Authors: Robert B Jenkins; Yuanyuan Xiao; Hugues Sicotte; Paul A Decker; Thomas M Kollmeyer; Helen M Hansen; Matthew L Kosel; Shichun Zheng; Kyle M Walsh; Terri Rice; Paige Bracci; Lucie S McCoy; Ivan Smirnov; Joseph S Patoka; George Hsuang; Joe L Wiemels; Tarik Tihan; Alexander R Pico; Michael D Prados; Susan M Chang; Mitchel S Berger; Alissa A Caron; Stephanie R Fink; Chandralekha Halder; Amanda L Rynearson; Brooke L Fridley; Jan C Buckner; Brian P O'Neill; Caterina Giannini; Daniel H Lachance; John K Wiencke; Jeanette E Eckel-Passow; Margaret R Wrensch Journal: Nat Genet Date: 2012-08-26 Impact factor: 41.307
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300
Authors: Gerald F Reis; Melike Pekmezci; Helen M Hansen; Terri Rice; Roxanne E Marshall; Annette M Molinaro; Joanna J Phillips; Hannes Vogel; John K Wiencke; Margaret R Wrensch; Kyle M Walsh; Arie Perry Journal: J Neuropathol Exp Neurol Date: 2015-05 Impact factor: 3.685
Authors: Elizabeth B Claus; Kyle M Walsh; John K Wiencke; Annette M Molinaro; Joseph L Wiemels; Joellen M Schildkraut; Melissa L Bondy; Mitchel Berger; Robert Jenkins; Margaret Wrensch Journal: Neurosurg Focus Date: 2015-01 Impact factor: 4.047
Authors: Kyle M Walsh; John K Wiencke; Daniel H Lachance; Joseph L Wiemels; Annette M Molinaro; Jeanette E Eckel-Passow; Robert B Jenkins; Margaret R Wrensch Journal: Neuro Oncol Date: 2015-05-25 Impact factor: 12.300
Authors: Terri Rice; Daniel H Lachance; Annette M Molinaro; Jeanette E Eckel-Passow; Kyle M Walsh; Jill Barnholtz-Sloan; Quinn T Ostrom; Stephen S Francis; Joseph Wiemels; Robert B Jenkins; John K Wiencke; Margaret R Wrensch Journal: Neurooncol Pract Date: 2015-08-25
Authors: Kyle M Walsh; Terri Rice; Paul A Decker; Matthew L Kosel; Thomas Kollmeyer; Helen M Hansen; Shichun Zheng; Lucie S McCoy; Paige M Bracci; Erik Anderson; George Hsuang; Joe L Wiemels; Alexander R Pico; Ivan Smirnov; Annette M Molinaro; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Daniel H Lachance; Hugues Sicotte; Jeanette E Eckel-Passow; John K Wiencke; Robert B Jenkins; Margaret R Wrensch Journal: Neuro Oncol Date: 2013-06-03 Impact factor: 12.300